Loading...
Market
Total number of Hillchol (BBV131) doses distributed worldwide by the end of 2024?
2
Resolution / Starting Odds
0-10 million doses • 25%
10-20 million doses • 25%
20-30 million doses • 25%
30+ million doses • 25%
Bharat Biotech official reports and global health organization statistics
Story
Bharat Biotech Launches Hillchol (BBV131) Oral Cholera Vaccine After Successful Trials
Aug 27, 2024, 10:39 AM
Indian vaccine manufacturer Bharat Biotech has announced the launch of its novel oral cholera vaccine, Hillchol (BBV131), following successful phase 3 trials. The vaccine, developed under license from Hilleman Laboratories, aims to address the rising global cholera cases and deaths, which have been increasing since 2021. Between early 2023 and March 2024, 824,479 cases and 5,900 deaths were reported across 31 countries. The introduction of this low-cost vaccine is considered a significant milestone in global public health efforts to combat cholera.
View original story
Similar markets
Less than 10 million doses • 25%
10-20 million doses • 25%
20-30 million doses • 25%
More than 30 million doses • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 50,000 • 25%
50,000 to 99,999 • 25%
100,000 to 150,000 • 25%
More than 150,000 • 25%
0-5 million doses • 25%
5.1-10 million doses • 25%
10.1-15 million doses • 25%
15.1+ million doses • 25%
1-5 • 25%
6-10 • 25%
11-15 • 25%
More than 15 • 25%
Less than 1 million • 25%
1 million to 3 million • 25%
3 million to 5 million • 25%
More than 5 million • 25%
Less than 1 million • 25%
1 to 3 million • 25%
3 to 5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 1.5 million • 25%
More than 1.5 million • 25%